Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bertrand Billemont

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Cancer Chemotherapy and Pharmacology|July 10, 2009
Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patientsRomain Coriat, Olivier Mir, Sandra Camps, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 4, 2009
Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasmaBenoit Blanchet, Carole Saboureau, Anne Sophie Benichou, et al.
The Oncologist|July 4, 2012
Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysisPascaline Boudou-Rouquette, Stanislas Ropert, Olivier Mir, et al.
The Oncologist|August 3, 2011
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activityOlivier Mir, Romain Coriat, Laure Cabanes, et al.
Bulletin Du Cancer|November 21, 2022
[Needs assessment for the establishment of an Oral Therapy Unit]Léa Vazquez, Julie Coussirou, Julien Grenier, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2012
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumoursEric Van Cutsem, David Khayat, Chris Verslype, et al.
Investigational New Drugs|October 19, 2011
Saturable absorption of sorafenib in patients with solid tumors: a population modelMarilyne Hornecker, Benoit Blanchet, Bertrand Billemont, et al.
The Journal of Urology|November 16, 2010
Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factorsGabriel G Malouf, Philippe Camparo, Vincent Molinié, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Cancer Chemotherapy and Pharmacology|July 10, 2009
Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patientsRomain Coriat, Olivier Mir, Sandra Camps, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|April 4, 2009
Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasmaBenoit Blanchet, Carole Saboureau, Anne Sophie Benichou, et al.
The Oncologist|July 4, 2012
Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysisPascaline Boudou-Rouquette, Stanislas Ropert, Olivier Mir, et al.
The Oncologist|August 3, 2011
An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activityOlivier Mir, Romain Coriat, Laure Cabanes, et al.
Bulletin Du Cancer|November 21, 2022
[Needs assessment for the establishment of an Oral Therapy Unit]Léa Vazquez, Julie Coussirou, Julien Grenier, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2012
Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumoursEric Van Cutsem, David Khayat, Chris Verslype, et al.
Investigational New Drugs|October 19, 2011
Saturable absorption of sorafenib in patients with solid tumors: a population modelMarilyne Hornecker, Benoit Blanchet, Bertrand Billemont, et al.
The Journal of Urology|November 16, 2010
Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factorsGabriel G Malouf, Philippe Camparo, Vincent Molinié, et al.
Pageof 2